Richard Christopher - InVivo Therapeutics CFO, Treasurer
| NVIVDelisted Stock | USD 1.38 0.07 5.34% |
CFO
Mr. Richard C. Christopher is Chief Financial Officer, Treasurer of the company. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a Nasdaqlisted company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD, Inc., Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology. Prior to Caliber, Mr. Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a Nasdaqlisted dermatology company focused on the treatment of precancerous skin lesions, where he ultimately served as Chief Financial Officer through its acquisition and integration into Sun Pharmaceuticals Industries Ltd since 2019.
| Age | 54 |
| Tenure | 5 years |
| Phone | 617 863 5500 |
| Web | https://www.invivotherapeutics.com |
Richard Christopher Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Christopher against InVivo Therapeutics stock is an integral part of due diligence when investing in InVivo Therapeutics. Richard Christopher insider activity provides valuable insight into whether InVivo Therapeutics is net buyers or sellers over its current business cycle. Note, InVivo Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell InVivo Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Christopher a day ago Disposition of 200000 shares by Richard Christopher of Lexaria Bioscience at 3.92 subject to Rule 16b-3 | ||
Richard Christopher 2 days ago Disposition of 200000 shares by Richard Christopher of Lexaria Bioscience at 3.92 subject to Rule 16b-3 | ||
Richard Christopher few days ago Disposition of 200000 shares by Richard Christopher of Lexaria Bioscience at 3.92 subject to Rule 16b-3 | ||
Richard Christopher few days ago Disposition of 200000 shares by Richard Christopher of Lexaria Bioscience at 3.92 subject to Rule 16b-3 |
InVivo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5371) % which means that it has lost $0.5371 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9811) %, meaning that it created substantial loss on money invested by shareholders. InVivo Therapeutics' management efficiency ratios could be used to measure how well InVivo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.InVivo Therapeutics Holdings currently holds 949 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. InVivo Therapeutics has a current ratio of 5.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about InVivo Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 3 records | CFO Age | ||
| Michael King | SAB Biotherapeutics | 63 | |
| Yvonne MBA | Senti Biosciences | 64 | |
| Esther Rajavelu | Spero Therapeutics | 45 | |
Management Performance
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 |
InVivo Therapeutics Leadership Team
Elected by the shareholders, the InVivo Therapeutics' board of directors comprises two types of representatives: InVivo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InVivo. The board's role is to monitor InVivo Therapeutics' management team and ensure that shareholders' interests are well served. InVivo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InVivo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jerome Gangitano, VP Operations | ||
| Joseph MD, CoFounder | ||
| Richard Christopher, CFO, Treasurer | ||
| Dr Langer, CoFounder Board | ||
| MD FACP, Consultant | ||
| Heather JD, Chief Counsel | ||
| Richard MD, CEO and Presidentident | ||
| Richard Toselli, Chief Medical Officer | ||
| Joseph Vacanti, CoFounder |
InVivo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is InVivo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | (7.59 M) | |||
| Shares Outstanding | 3.11 M | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 3.44 % | |||
| Number Of Shares Shorted | 17.63 K | |||
| Price To Earning | (1.90) X | |||
| Price To Book | 0.1 X | |||
| EBITDA | (9.8 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |